Table of Contents
NORTH WALES, Pa. — Teva Pharmaceuticals USA has launched a U.S. prescription co-payment assistance program in the U.S. for its imatinib mesylate tablets, a cancer treatment.
People who meet certain requirements are eligible for the program and may pay as little as $0 out of pocket, with a maximum benefit of up to $700 per fill, according to Teva. The program applies to eligible patients who are commercially insured, and savings are limited to the co-pay amount.
Teva launched its imatinib mesylate tablets, a generic version of Gleevec tablets from Novartis, in the United States earlier this year.
“This effort further reinforces Teva’s long-standing commitment to providing access to our medicines,” stated Andy Boyer, president and chief executive officer of global generic medicines for North America at Teva. “Given today’s economic climate, programs that help alleviate the high co-pay costs that many patients face are increasingly important.”
Imatinib mesylate tablets interefere with the growth of some cancer cells and are used to treat forms of leukemia, bone marrow disorders and skin cancer, as well as certain tumors of the stomach and digestive system.
